A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder

Trial Profile

A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs TA 5538 (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 01 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top